vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer
HIGH POINT, N.C. and WESTON, FL– June 22, 2021 – vTv Therapeutics Inc. ("vTv", Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. ("Cantex") today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv's novel antagonist of RAGE (the receptor...
22 June, 2021